BTAI

Peers: VRTX REGN AMGN BIIB INCY NBIX SAGE ACAD ONC EXEL

Index	-	P/E	-	EPS (ttm)	-7.15	Insider Own	3.89%	Shs Outstand	27.07M	Perf Week	-13.87%
Market Cap	31.95M	Forward P/E	-	EPS next Y	-1.65	Insider Trans	0.00%	Shs Float	26.02M	Perf Month	-28.48%
Enterprise Value	122.60M	PEG	-	EPS next Q	-0.62	Inst Own	14.31%	Short Float	10.78%	Perf Quarter	-26.25%
Income	-69.90M	P/S	49.92	EPS this Y	60.51%	Inst Trans	2.02%	Short Ratio	1.98	Perf Half Y	-54.09%
Sales	0.64M	P/B	-	EPS next Y	27.07%	ROA	-162.82%	Short Interest	2.80M	Perf YTD	-26.25%
Book/sh	-4.28	P/C	1.11	EPS next 5Y	48.12%	ROE	-	52W High	8.08 -85.40%	Perf Year	-40.70%
Cash/sh	1.06	P/FCF	-	EPS past 3/5Y	60.75% 37.62%	ROIC	-	52W Low	1.15 2.61%	Perf 3Y	-99.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	19.63% -	Gross Margin	27.73%	Volatility	13.75% 10.63%	Perf 5Y	-99.80%
Dividend TTM	-	EV/Sales	191.56	EPS Y/Y TTM	72.40%	Oper. Margin	-7742.21%	ATR (14)	0.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.82	Sales Y/Y TTM	-71.67%	Profit Margin	-10887.38%	RSI (14)	35.02	Recom	1.60
Dividend Gr. 3/5Y	- -	Current Ratio	0.83	EPS Q/Q	71.24%	SMA20	-19.48%	Beta	0.37	Target Price	14.60
Payout	-	Debt/Eq	-	Sales Q/Q	-30.05%	SMA50	-24.41%	Rel Volume	0.72	Prev Close	1.22
Employees	29	LT Debt/Eq	-	Earnings	Mar 27 BMO	SMA200	-47.86%	Avg Volume	1.42M	Price	1.18
IPO	Mar 08, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	8.66% 68.98%	Trades		Volume	1,020,337	Change	-3.28%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-17-26	Initiated	Rodman & Renshaw	Buy	$17
Feb-21-24	Downgrade	UBS	Buy → Neutral	$9 → $4
Aug-15-23	Downgrade	Mizuho	Buy → Neutral	$40 → $4
Jul-17-23	Downgrade	Guggenheim	Buy → Neutral
Mar-10-23	Downgrade	Jefferies	Buy → Hold	$20 → $22
Dec-01-22	Upgrade	Goldman	Sell → Neutral	$16
Jul-07-22	Initiated	Mizuho	Buy	$19
Apr-06-22	Reiterated	BofA Securities	Buy	$80
Nov-15-21	Downgrade	Goldman	Neutral → Sell	$55 → $24
Apr-09-21	Initiated	Berenberg	Buy	$75
Feb-01-21	Initiated	UBS	Buy	$99
Oct-30-20	Initiated	Goldman	Buy	$60
Sep-02-20	Initiated	Jefferies	Buy	$82
Aug-17-20	Reiterated	H.C. Wainwright	Buy	$200 → $175
Jul-08-20	Reiterated	H.C. Wainwright	Buy	$95 → $120
Jun-04-20	Initiated	Guggenheim	Buy	$101
Apr-01-20	Initiated	BofA/Merrill	Buy	$45
Feb-26-20	Reiterated	H.C. Wainwright	Buy	$30 → $95
Jan-08-20	Reiterated	H.C. Wainwright	Buy	$25 → $30
Nov-12-19	Initiated	SunTrust	Buy	$24

Show Previous Ratings

Apr-01-26 07:00AM	BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting (GlobeNewswire) -8.96%
Mar-27-26 07:00AM	BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI Approval in Outpatient Setting (GlobeNewswire) -8.03%
Mar-11-26 04:20PM	BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering (GlobeNewswire)
Mar-10-26 02:36PM	BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering (GlobeNewswire) -10.40%
Mar-06-26 10:27AM	Why Are BioXcel Therapeutics Shares Down Friday? (Benzinga) -8.07%
08:53AM	Loading…
Mar-05-26 08:53AM	BioXcel Therapeutics Stock Rallies Opioid Study Success (Benzinga)
07:00AM	BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal (GlobeNewswire)
Feb-19-26 07:00AM	BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia (GlobeNewswire)
Feb-12-26 07:00AM	BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI in the At-Home Setting (GlobeNewswire)
Jan-20-26 07:00AM	BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI Label Expansion in the At-Home Setting (GlobeNewswire)
Jan-17-26 12:00PM	1 Top Penny Stock to Watch Now (Barchart)
Jan-15-26 12:44PM	Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Jan-12-26 07:00AM	BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI in the At-Home Setting (GlobeNewswire)
Jan-07-26 07:00AM	BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI (GlobeNewswire) +17.24%
Dec-03-25 07:00AM	Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions (GlobeNewswire)
08:25AM	Loading…
Nov-12-25 08:25AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -15.35%
07:00AM	BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease (GlobeNewswire)
Oct-24-25 11:38AM	Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-14-25 07:00AM	BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes (GlobeNewswire)
Oct-13-25 07:00AM	BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation (GlobeNewswire)
Sep-18-25 07:00AM	BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements (GlobeNewswire)
Sep-10-25 06:30AM	BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
Sep-04-25 07:00AM	BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-29-25 07:28AM	BioXCel seeks Igalmi label expansion after Phase III success (Clinical Trials Arena)
Aug-27-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -24.43%
08:00AM	UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI (GlobeNewswire)
07:00AM	BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI (GlobeNewswire)
Aug-26-25 04:00PM	BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025 (GlobeNewswire)
Aug-19-25 07:00AM	BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire) -13.23%
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:00AM	Loading…
07:00AM	BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
Aug-13-25 12:33PM	3 Supercharged Stocks Flashing Strong Momentum Signals (Benzinga) -17.65%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:00AM	BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. "HCW@Home" Series (GlobeNewswire)
Aug-12-25 03:00PM	BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.25%
07:55AM	BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates (GlobeNewswire)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +58.42%
07:00AM	BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Aug-08-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +18.48%
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-06-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +11.78%
07:00AM	BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies (GlobeNewswire)
Aug-04-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +85.40%
Aug-01-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:00AM	BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
Jul-21-25 07:00AM	BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI (GlobeNewswire)
Jul-14-25 11:33AM	FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks (Zacks)
Jul-11-25 07:27PM	BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress (Insider Monkey)
Jul-01-25 07:00AM	BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire) +8.84%
May-30-25 09:09AM	Real-World Deployments Signal AI Healthcare Is Ready for Scale (PR Newswire)
May-27-25 08:01AM	BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
07:00AM	BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement (GlobeNewswire)
May-12-25 08:15AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-06-25 09:15AM	Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates (Zacks) -7.60%
May-05-25 05:15PM	Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-16-25 08:58AM	WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market (PR Newswire)
Mar-27-25 08:15AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.96%
07:00AM	BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 (GlobeNewswire)
Mar-20-25 06:50PM	TELA Bio, Inc. (TELA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Mar-19-25 05:10PM	ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +7.73%
02:13PM	Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight (Zacks)
Mar-11-25 07:00AM	BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire) -16.84%
Mar-09-25 06:05PM	Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week (Insider Monkey)
Mar-07-25 07:00AM	BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire) +22.99%
Mar-04-25 04:15PM	BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering (GlobeNewswire) -28.00%
10:00AM	BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Mar-03-25 03:33PM	BioXcel Therapeutics Announces $14 Million Registered Direct Offering (GlobeNewswire) +73.61%
07:00AM	BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia (GlobeNewswire)
Feb-28-25 07:00AM	BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire) +24.86%
Feb-06-25 07:00AM	BioXcel Therapeutics Announces Reverse Stock Split (GlobeNewswire) -37.57%
Feb-05-25 07:00AM	BioXcel Therapeutics Provides Clinical and Business Update (GlobeNewswire)
Dec-23-24 12:00PM	BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Nov-22-24 08:16AM	BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering (GlobeNewswire) -10.80%
Nov-21-24 04:47PM	BioXcel Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Nov-15-24 02:07AM	BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... (GuruFocus.com) +9.20%
Nov-14-24 11:13PM	Q3 2024 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -15.93%
08:20AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	BioXcel Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-13-24 07:31AM	What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings (GuruFocus.com) -6.92%
Nov-12-24 07:00AM	BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia (GlobeNewswire) -7.61%
Nov-08-24 07:00AM	BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 (GlobeNewswire)
Nov-05-24 10:00AM	Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-29-24 07:00AM	BioXcel Therapeutics to Present at ThinkEquity Conference (GlobeNewswire) +6.57%
Oct-15-24 07:00AM	BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder (GlobeNewswire) +6.06%
Sep-19-24 07:00AM	BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation (GlobeNewswire)
Sep-12-24 01:22AM	FMR LLC's Strategic Reduction in BioXcel Therapeutics Inc Shares (GuruFocus.com)
Sep-05-24 07:00AM	BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
Aug-30-24 09:55AM	BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-07-24 07:00AM	BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire) -5.06%
01:31AM	Q2 2024 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-06-24 08:10AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	BioXcel Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 07:00AM	BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire) -6.84%
Jul-16-24 07:00AM	BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI (dexmedetomidine) Sublingual Film (GlobeNewswire) +9.84%
Jun-25-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
May-28-24 07:00AM	BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-24 07:00AM	BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (GlobeNewswire)
May-10-24 11:58AM	BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript (Insider Monkey) -9.33%

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BioXcel Therapeutics Inc

Upgrade your Finviz experience